Dr Reddys Laboratories Ltd
RDY- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001135951
No open-market purchases or sales by Dr Reddys Laboratories Ltd insiders were filed in the last 90 days; 239 institutions reported holding it in 13F filings for Q2 2026, worth $1.82B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −6 vs. previous quarter
- 239
- 13F valueReported value at the end of Q2 2026
- $1.82B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding RDY, Q2 2026
No superinvestor reported holding RDY at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Dr Reddys Laboratories Ltd insiders from Form 4, newest first.
No open-market purchases or sales by Dr Reddys Laboratories Ltd insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Dr Reddys Laboratories Ltd at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Robeco Institutional Asset Management B.V. | 18,021,100 | $261.1M | 0.32% | +843,218+4.9% | Added |
| Morgan Stanley | 10,936,320 | $158.5M | 0.01% | +1,564,726+16.7% | Added |
| BlackRock, Inc. | 10,585,742 | $153.4M | 0.00% | −1,001,385−8.6% | Reduced |
| Royal Bank of Canada | 9,213,269 | $133.5M | 0.02% | −770,813−7.7% | Reduced |
| Aikya Investment Management Ltd | 8,493,852 | $123.1M | 36.13% | +494,056+6.2% | Added |
| Renaissance Technologies LLC | 7,347,028 | $106.5M | 0.15% | −512,700−6.5% | Reduced |
| Dimensional Fund Advisors LP | 5,312,065 | $77.0M | 0.01% | −11,183−0.2% | Reduced |
| JPMorgan Chase & Co | 4,069,357 | $60.5M | 0.00% | −302,021−6.9% | Reduced |
| State Street Corp | 4,124,686 | $59.8M | 0.00% | +98,479+2.4% | Added |
| Alliancebernstein L.P. | 3,730,713 | $51.7M | 0.02% | +1,188,824+46.8% | Added |